18 / 136
Washington H. Soul Pattinson and Company Limited
Annual Report 2016
16
API’s financial year ended on 31 August 2016. The results for the full year were released to the market on
20 October 2016.
For the six months ended 29 February 2016, API reported the following results which are compared to those
of the first half last year:
4
Total revenue of $1.8 billion, up 4.4%;
4
Earnings before interest and tax of $44.6 million, up 15.6%;
4
Underlying net profit after tax of $25.3 million, up 18.1%; and
4
Net profit after tax of $22.9 million, up 7.7%.
API attributed this strong growth to its strategy which is centred on building the Priceline Pharmacy network
while generating sustainable returns through its pharmaceutical distribution.
In June API paid a fully franked interim dividend of 2.5 cents per share, an increase of 25% over last year.
WHSP has equity accounted API’s result for the 12 months to 28 February 2016. API contributed a net profit
of $11.0 million (2015: $11.3 million) to the Group. Its contribution to regular profit was $11.6 million (2015:
$9.2 million).
Australian Pharmaceutical
Industries Limited
Associated entity:
24.6% held
Dividends paid to WHSP:
$6 million
Total Market Capitalisation:
$939 million
Value of WHSP’s Holding:
$231 million
ASX code:
API
NETPROFIT
CONTRIBUTED
TOTHEGROUP
$11m
api